NAUS-EASE

Manufacturer
Sunascen Therapeutics LLC
Effective date
2023-02-09
Label type
HUMAN OTC DRUG LABEL
Version
16
Source
full-release
Hydrated at
2026-05-31 23:53:48

Label at a glance#

ProductNAUS-EASE
Active ingredientMECLIZINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

For Consumers (the general public): Naus-Ease® (Meclizine Hydrochloride), USP Film Strips are used for the prevention and treatment of nausea and vomiting, or dizziness associated with motion sickness. For Health Professionals: Based on a review of Meclizine Hydrochloride, USP drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications of Mecliz...

Dosage and administration

Adults and children 12 years of age and over: Take 1 to 2 Naus-Ease® (Meclizine Hydrochloride), USP Film Strips (25 mg to 50 mg) once daily, or as directed by a physician. Place a film strip on the tongue. Allow each film strip to completely dissolve, and then swallow. The initial dose of 25 mg to 50 mg of Naus-Ease® (Meclizine Hydrochloride), USP Film Strips should be taken one hour prior to travel for the preven...

Label contents#

Full prescribing information#

ACTIVE INGREDIENTS

OTC - ACTIVE INGREDIENT SECTION

Meclizine Hydrochloride, USP 25 mg

PURPOSE

OTC - PURPOSE SECTION

Antiemetic

DESCRIPTION

DESCRIPTION SECTION

Chemically, Meclizine Hydrochloride, USP is 1-( p-Chloro-α-phenylbenzyl)-4-( m-methylbenzyl) piperazine dihydrochloride monohydrate. Meclizine Hydrochloride, USP is an oral antiemetic, which is a white to slightly yellowish crystalline powder having a slight odor and is tasteless. The molecular weight is 481.89 g/mol. It has the following structural formula:

Meclizine Hydrochloride, USP Structural Formula
Meclizine Hydrochloride, USP Structural Formula

C 25H 27CIN 2·2HCl·H 20 M.W. 481.88544 g/mol

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Meclizine Hydrochloride, USP is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Pharmacokinetics

PHARMACOKINETICS SECTION

The available pharmacokinetic information for Meclizine Hydrochloride, USP following oral administration has been summarized from published literature.

Absorption

SPL UNCLASSIFIED SECTION

Meclizine Hydrochloride, USP is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

Distribution

SPL UNCLASSIFIED SECTION

Drug distribution characteristics for Meclizine Hydrochloride, USP in humans remains unknown.

Metabolism

SPL UNCLASSIFIED SECTION

The metabolic fate of Meclizine Hydrochloride, USP in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP 2D6 was found to be the dominant enzyme for metabolism of Meclizine Hydrochloride, USP.

The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in Meclizine Hydrochloride, USP exposure.

Elimination

SPL UNCLASSIFIED SECTION

Meclizine Hydrochloride, USP has a plasma elimination half-life of about 5-6 hours in humans.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For Consumers (the general public):
Naus-Ease® (Meclizine Hydrochloride), USP Film Strips are used for the prevention and treatment of nausea and vomiting, or dizziness associated with motion sickness.

For Health Professionals:
Based on a review of Meclizine Hydrochloride, USP drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications of Meclizine Hydrochloride, USP as follows:
1. The prevention and treatment (management) of nausea and vomiting, and dizziness associated with motion sickness.
2. For the treatment of vertigo.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Meclizine Hydrochloride, USP is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

WARNINGS SECTION

Clinical studies establishing safety and effectiveness in children under 12 years of age have not been done; therefore, usage is not recommended in children under 12 years of age unless directed by a doctor.

Due to its potential anticholinergic action, do not take unless directed by a doctor if you have a breathing problem such as asthma, emphysema, or chronic bronchitis, glaucoma, or difficulty in urination due to enlargement of the prostate gland.

Ask a doctor before use if you are taking sedatives or tranquilizers.

When using this product:
1. Do not exceed the recommended dosage.
2. May cause drowsiness.
3. Patients should avoid alcoholic beverages while taking this drug.
4. Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery. Therefore patients are reminded caution when driving or operating machinery.
5. Alcohol, sedatives and tranquilizers may increase drowsiness.

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, seek medical help or contact a Poison Control Center right away.
Call Poison Control at 1-800-222-1222

PRECAUTIONS

PRECAUTIONS SECTION

Pediatric Use

PEDIATRIC USE SECTION

Clinical studies establishing safety and effectiveness in children under 12 years of age have not been done; therefore, usage is not recommended in children under 12 years of age unless directed by a doctor.

Pregnancy Use

PREGNANCY SECTION

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25 to 50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that Meclizine Hydrochloride, USP increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, Meclizine Hydrochloride, USP or any other medication, should be used during pregnancy only if clearly necessary, and after speaking with a health professional.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Meclizine Hydrochloride, USP is administered to a nursing woman.

Hepatic Impairment

SPL UNCLASSIFIED SECTION

The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As Meclizine Hydrochloride, USP undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with Meclizine Hydrochloride, USP should be administered with caution in patients with hepatic impairment.

Renal Impairment

SPL UNCLASSIFIED SECTION

The effect of renal impairment on the pharmacokinetics of Meclizine Hydrochloride, USP has not been evaluated. Due to a potential for drug/metabolite accumulation, Meclizine Hydrochloride, USP should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.

Drug Interactions

SPL UNCLASSIFIED SECTION

There may be increased CNS depression when Meclizine Hydrochloride, USP is administered concurrently with other CNS depressants, including alcohol, tranquilizers and sedatives. (see WARNINGS)

Based on in vitro evaluation, Meclizine Hydrochloride, USP is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between Meclizine Hydrochloride, USP and CYP2D6 inhibitors.

KEEP OUT OF REACH OF CHILDREN

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of an overdose, seek medical help or contact a Poison Control Center immediately.
Call Poison Control at 1-800-222-1222.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION (DIRECTIONS)

DOSAGE & ADMINISTRATION SECTION

Adults and children 12 years of age and over: Take 1 to 2 Naus-Ease® (Meclizine Hydrochloride), USP Film Strips (25 mg to 50 mg) once daily, or as directed by a physician. Place a film strip on the tongue. Allow each film strip to completely dissolve, and then swallow.

The initial dose of 25 mg to 50 mg of Naus-Ease® (Meclizine Hydrochloride), USP Film Strips should be taken one hour prior to travel for the prevention and treatment of motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

INACTIVE INGREDIENTS

INACTIVE INGREDIENT SECTION

Polyethylene oxide, Hydroxypropyl methylcellulose, Maltitol, Citric acid, Sodium citrate, and FD&C green #3.

HOW SUPPLIED

HOW SUPPLIED SECTION

Naus-Ease® (Meclizine Hydrochloride), USP Film Strips are available in 25mg strengths. Each Film Strip is individualy wrapped in a pouch, and is available in 8 and 16 count package sizes.

25 mg (Green rectangular shaped, with "S1" printed on each film strip)

Naus-Ease® (Meclizine Hydrochloride), USP; 8 Film Strips: NDC 49467-104-01
Naus-Ease® (Meclizine Hydrochloride), USP; 16 Film Strips: NDC 49467-104-16

Distributed by:
Sunascen Therapeutics LLC
Rockville, MD 20850 USA

QUESTIONS OR COMMENTS?

OTC - QUESTIONS SECTION

Sunascen Therapeutics LLC
Call us toll free at 1-833-SUNASCN (786-2726) Mon-Fri 9am-5pm EST.
Email us at ConsumerCare@Sunascen.com
More information is available on our website at www.sunascen.com


PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Naus-Ease® (Meclizine Hydrochloride), USP; Film Strips 25 mg Each
Antiemetic – Prevent and Treat: Nausea and Vomiting

TAMPER EVIDENT: EACH FILM STRIP IS INDIVIDUALLY SEALED IN A POUCH. DO NOT USE IF INDIVIDUAL POUCH IS TORN, BROKEN, OR SHOWS ANY SIGNS OF TAMPERING.

Note:
Store at controlled room temperature 20-30°C. (68-86°F)
Protect from heat and humidity
Use by the expiration date on the package

Naus-Ease® (Meclizine Hydrochloride), USP - Film Strip Carton Image
Naus-Ease® (Meclizine Hydrochloride), USP - Film Strip Carton Image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
996062meclizine HCl 25 MG Oral FilmPSN16
996062meclizine hydrochloride 25 MG Oral FilmSCD16

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
MECLIZINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
ac6963c4-31c6-325f-ee58-83a0a06597adProduct name520221206
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906Product name720210625
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
49467-104-01NAUS-EASE8 in 1 CARTONFILM, SOLUBLE816
49467-104-01NAUS-EASE1 in 1 POUCHFILM, SOLUBLE116
49467-104-16NAUS-EASE1 in 1 POUCHFILM, SOLUBLE116
49467-104-16NAUS-EASE16 in 1 CARTONFILM, SOLUBLE1616

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
49467-104NAUS-EASE (MECLIZINE HYDROCHLORIDE) FILM, SOLUBLE [SUNASCEN THERAPEUTICS LLC]16Legacy NDC, 4 package rows20230211_45ed34ea-457f-4d7e-8d2f-2c3ff5054a87.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
MECLIZINE HYDROCHLORIDEACTIVE INGREDIENTHDP7W44CIO7
MECLIZINEACTIVE MOIETY3L5TQ845707
ACESULFAME POTASSIUMINACTIVE INGREDIENT23OV73Q5G97
ANHYDROUS CITRIC ACIDINACTIVE INGREDIENTXF417D3PSL7
ANHYDROUS TRISODIUM CITRATEINACTIVE INGREDIENTRS7A450LGA7
HYPROMELLOSESINACTIVE INGREDIENT3NXW29V3WO7
MALTITOLINACTIVE INGREDIENTD65DG142WK7
POLYETHYLENE GLYCOLSINACTIVE INGREDIENT3WJQ0SDW1A7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
49467-10449467-104-01, 49467-104-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 142 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9SOLUTION / DENTAL0.12 %w/wExact identifier — unii candidate
17 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, CHEWABLE, EXTENDED RELEASE / ORAL12 mgExact identifier — unii candidate
61 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOCAPSULE, EXTENDED RELEASE / ORAL119.7 mgExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGAINJECTION / INTRABURSAL1 %w/vExact identifier — unii candidate
30 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOSUSPENSION / ORAL305 mgExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION / ORAL3900 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLPOWDER, FOR SUSPENSION / ORAL570 mgExact identifier — unii candidate
61 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9TABLET, ORALLY DISINTEGRATING / ORAL24 mgExact identifier — unii candidate
17 equally ranked IID candidates
MALTITOLMALTITOLD65DG142WKTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
7 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGAINJECTION / INTRAVENOUS792 mgExact identifier — unii candidate
30 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOJELLY / TOPICALNAExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCLOTH / TOPICAL4.2 mgExact identifier — unii candidate
61 equally ranked IID candidates
MALTITOLMALTITOLD65DG142WKSOLUTION / ORAL9000 mgExact identifier — unii candidate
7 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9POWDER, FOR SOLUTION / ORAL117 mgExact identifier — unii candidate
17 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM / SUBLINGUAL11 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGACONCENTRATE / INTRAVENOUS24 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS414 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGAGRANULE, FOR SUSPENSION / ORAL4000 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCREAM / TOPICAL1 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION / RESPIRATORY (INHALATION)5 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGACREAM / TOPICAL4 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION / SUBCUTANEOUS25 mgExact identifier — unii candidate
61 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOSYSTEM / TOPICAL54 mgExact identifier — unii candidate
27 equally ranked IID candidates
MALTITOLMALTITOLD65DG142WKFILM, SOLUBLE / ORAL44 mgExact identifier — unii candidate
7 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET / ORAL197 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INTRAVENOUS1152 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCAPSULE, LIQUID FILLED / ORAL360 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION/ DROPS / AURICULAR (OTIC)1 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSYRUP / ORAL268 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / PERINEURAL0.02 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGASUSPENSION / ORAL21 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION / RECTAL904 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGAPOWDER, FOR SOLUTION / ORAL48 mg/5mlExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGALOTION / TOPICAL0.08 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGASUSPENSION / RESPIRATORY (INHALATION)2 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLGRANULE, FOR SUSPENSION / ORAL30 mgExact identifier — unii candidate
61 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOSUSPENSION / OPHTHALMIC0.5 %w/wExact identifier — unii candidate
27 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOCAPSULE, DELAYED RELEASE / ORAL105 mgExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION / TOPICAL4.35 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM, SOLUBLE / ORAL7 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLELIXIR / ORAL90 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLLOZENGE / TRANSMUCOSAL44 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY, METERED / NASAL1.2 mg/1mlExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, CHEWABLE / ORAL4 mgExact identifier — unii candidate
61 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOCAPSULE / ORAL1488 mgExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY / NASAL5 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLOIL / TOPICAL2 mgExact identifier — unii candidate
61 equally ranked IID candidates
MALTITOLMALTITOLD65DG142WKGUM, CHEWING / BUCCAL4932 mgExact identifier — unii candidate
7 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGATABLET / SUBLINGUAL36 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGATABLET, CHEWABLE / ORAL72.5 mgExact identifier — unii candidate
30 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INFILTRATION0.02 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGAINJECTION / INTRA-ARTICULAR22 mgExact identifier — unii candidate
30 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9FILM / SUBLINGUAL5 mgExact identifier — unii candidate
17 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION / INTRAVENOUS772 mgExact identifier — unii candidate
61 equally ranked IID candidates
MALTITOLMALTITOLD65DG142WKFILM / SUBLINGUAL24 mgExact identifier — unii candidate
7 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION, CONCENTRATE / INTRAVENOUS60 mgExact identifier — unii candidate
61 equally ranked IID candidates
ACESULFAME POTASSIUMACESULFAME POTASSIUM23OV73Q5G9FILM, SOLUBLE / ORAL10 mgExact identifier — unii candidate
17 equally ranked IID candidates
HYPROMELLOSESHYPROMELLOSE3NXW29V3WOTABLET, CHEWABLE / ORAL11.8 mgExact identifier — unii candidate
27 equally ranked IID candidates
ANHYDROUS TRISODIUM CITRATEANHYDROUS TRISODIUM CITRATERS7A450LGASOLUTION, CONCENTRATE / INTRAVENOUS24 mgExact identifier — unii candidate
30 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
f44fafc4-59c1-be97-e053-2a95a90a116245ed34ea-457f-4d7e-8d2f-2c3ff5054a872023-02-09Warnings, Adverse reactionsExact identifier
spl id: f44fafc4-59c1-be97-e053-2a95a90a1162
spl set id: 45ed34ea-457f-4d7e-8d2f-2c3ff5054a87

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.